NCT02193113 - A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2014

Primary Completion Date

June 4, 2015

Study Completion Date

June 4, 2015

Conditions

Diabetic Macular Edema

Interventions

DRUG

KVD001 Injection

A novel plasma kallikrein inhibitor

Trial Locations (5)

Palmetto Retina Center, West Columbia

Raj K. Maturi, MD PC, Indianapolis

Valley Retina Institute, PA, McAllen

Retina Vitreous Associates Medical Group, Beverly Hills

Beetham Eye Institute, Boston